Dr Reddy's Laboratories Net Profit Margin 2012-2026 | RDY
Current and historical net profit margin for Dr Reddy's Laboratories (RDY) from 2012 to 2026. Net profit margin can be defined as net Income as a portion of total sales revenue. Dr Reddy's Laboratories net profit margin for the three months ending March 31, 2026 was .
| Dr Reddy's Laboratories Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2026-03-31 | $3.58B | $0.46B | 12.71% |
| 2025-12-31 | $3.94B | $0.65B | 16.41% |
| 2025-09-30 | $3.95B | $0.68B | 17.18% |
| 2025-06-30 | $3.89B | $0.66B | 17.03% |
| 2025-03-31 | $3.81B | $0.66B | 17.40% |
| 2024-12-31 | $3.70B | $0.64B | 17.21% |
| 2024-09-30 | $3.58B | $0.63B | 17.73% |
| 2024-06-30 | $3.45B | $0.66B | 19.22% |
| 2024-03-31 | $3.35B | $0.67B | 19.91% |
| 2023-12-31 | $3.23B | $0.62B | 19.21% |
| 2023-09-30 | $3.19B | $0.61B | 19.04% |
| 2023-06-30 | $3.15B | $0.57B | 18.05% |
| 2023-03-31 | $2.99B | $0.55B | 18.32% |
| 2022-12-31 | $2.95B | $0.45B | 15.14% |
| 2022-09-30 | $2.83B | $0.39B | 13.73% |
| 2022-06-30 | $2.82B | $0.38B | 13.60% |
| 2022-03-31 | $2.83B | $0.31B | 11.00% |
| 2021-12-31 | $2.83B | $0.36B | 12.69% |
| 2021-09-30 | $2.79B | $0.27B | 9.58% |
| 2021-06-30 | $2.67B | $0.24B | 8.84% |
| 2021-03-31 | $2.59B | $0.24B | 9.10% |
| 2020-12-31 | $2.38B | $0.27B | 11.39% |
| 2020-09-30 | $2.32B | $0.19B | 8.10% |
| 2020-06-30 | $2.34B | $0.24B | 10.24% |
| 2020-03-31 | $2.32B | $0.26B | 11.18% |
| 2019-12-31 | $2.46B | $0.24B | 9.63% |
| 2019-09-30 | $2.38B | $0.38B | 16.14% |
| 2019-06-30 | $2.24B | $0.30B | 13.44% |
| 2019-03-31 | $2.23B | $0.27B | 12.22% |
| 2018-12-31 | $2.15B | $0.25B | 11.74% |
| 2018-09-30 | $2.20B | $0.24B | 10.77% |
| 2018-06-30 | $2.21B | $0.21B | 9.45% |
| 2018-03-31 | $2.18B | $0.15B | 6.92% |
| 2017-12-31 | $2.26B | $0.16B | 7.02% |
| 2017-09-30 | $2.22B | $0.18B | 7.93% |
| 2017-06-30 | $2.21B | $0.18B | 7.98% |
| 2017-03-31 | $2.17B | $0.19B | 8.57% |
| 2016-12-31 | $2.09B | $0.14B | 6.56% |
| 2016-09-30 | $2.15B | $0.16B | 7.27% |
| 2016-06-30 | $2.22B | $0.22B | 10.03% |
| 2016-03-31 | $2.34B | $0.30B | 12.93% |
| 2015-12-31 | $2.43B | $0.38B | 15.64% |
| 2015-09-30 | $2.44B | $0.38B | 15.72% |
| 2015-06-30 | $2.40B | $0.37B | 15.20% |
| 2015-03-31 | $2.40B | $0.36B | 14.98% |
| 2014-12-31 | $2.36B | $0.36B | 15.12% |
| 2014-09-30 | $2.32B | $0.37B | 15.76% |
| 2014-06-30 | $2.27B | $0.38B | 16.80% |
| 2014-03-31 | $2.17B | $0.35B | 16.20% |
| 2013-12-31 | $2.20B | $0.38B | 17.10% |
| 2013-09-30 | $2.15B | $0.35B | 16.05% |
| 2013-06-30 | $2.16B | $0.31B | 14.46% |
| 2013-03-31 | $2.14B | $0.31B | 14.56% |
| 2012-12-31 | $2.05B | $0.27B | 13.40% |
| 2012-09-30 | $2.05B | $0.30B | 14.77% |
| 2012-06-30 | $1.96B | $0.29B | 14.67% |
| 2012-03-31 | $1.95B | $0.29B | 14.72% |
| 2011-12-31 | $1.88B | $0.29B | 15.63% |
| 2011-09-30 | $1.78B | $0.26B | 14.47% |
| 2011-06-30 | $1.74B | $0.26B | 14.88% |
| 2011-03-31 | $1.66B | $0.25B | 14.76% |
| 2010-12-31 | $1.57B | $0.21B | 13.17% |
| 2010-09-30 | $1.52B | $0.03B | 2.24% |
| 2010-06-30 | $1.48B | $0.02B | 1.01% |
| 2010-03-31 | $1.50B | $0.02B | 1.40% |
| 2009-12-31 | $1.53B | $-0.21B | -13.63% |
| 2009-09-30 | $1.53B | $-0.06B | -3.66% |
| 2009-06-30 | $1.50B | $-0.08B | -5.01% |
| 2009-03-31 | $1.47B | $-0.10B | -6.48% |
| 2008-12-31 | $1.41B | $0.12B | 8.74% |
| 2008-09-30 | $1.34B | $0.06B | 4.62% |
| 2008-06-30 | $1.31B | $0.10B | 7.84% |
| 2008-03-31 | $1.26B | $0.12B | 9.29% |
| 2007-12-31 | $1.35B | $0.17B | 12.84% |
| 2007-09-30 | $2.16B | $0.33B | 15.39% |
| 2007-06-30 | $2.58B | $0.36B | 13.80% |
| 2007-03-31 | $2.59B | $0.34B | 13.17% |
| 2006-12-31 | $1.94B | $0.22B | 11.22% |
| 2006-09-30 | $0.95B | $0.09B | 9.89% |
| 2006-06-30 | $0.34B | $0.02B | 6.76% |
| 2006-03-31 | $0.16B | $0.00B | 0.62% |
| 2005-12-31 | $0.49B | $0.03B | 6.19% |
| 2005-09-30 | $0.47B | $0.03B | 6.33% |
| 2005-06-30 | $0.46B | $0.02B | 4.57% |
| 2005-03-31 | $0.44B | $0.02B | 3.83% |
| 2004-12-31 | $0.46B | $0.03B | 7.21% |
| 2004-09-30 | $0.45B | $0.03B | 7.08% |
| 2004-06-30 | $0.45B | $0.04B | 9.09% |
| 2004-03-31 | $0.44B | $0.05B | 12.19% |
| 2003-12-31 | $0.43B | $0.07B | 15.22% |
| 2003-09-30 | $0.41B | $0.07B | 16.54% |
| 2003-06-30 | $0.40B | $0.07B | 16.92% |
| 2003-03-31 | $0.39B | $0.08B | 19.48% |
| 2002-12-31 | $-1.98B | $-0.01B | 0.46% |
| 2002-09-30 | $-1.97B | $0.00B | -0.20% |
| 2002-06-30 | $-1.97B | $0.03B | -1.42% |
| 2002-03-31 | $0.34B | $0.10B | 29.71% |
| 2001-12-31 | $2.82B | $0.20B | 7.12% |
| 2001-09-30 | $2.84B | $0.19B | 6.58% |
| 2001-06-30 | $2.84B | $0.16B | 5.46% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.109B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |